Cannabidiol Modulation of ∆-9-THC's Psychotomimetic Effects in Healthy Humans
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Behavioral Measures
研究概览
简要总结
Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Exposed to Cannabis at least once in lifetime
排除标准
- •Cannabis Naive
研究组 & 干预措施
Active Canabidiol and Active Delta-9-THC
干预措施: Cannabidiol (Drug)
Active Canabidiol and Active Delta-9-THC
干预措施: Delta-9-THC (Drug)
Placebo and Active Delta-9-THC
干预措施: Delta-9-THC (Drug)
Placebo and Active Delta-9-THC
干预措施: Placebo (Drug)
Active Cannabidiol and Placebo
干预措施: Cannabidiol (Drug)
Active Cannabidiol and Placebo
干预措施: Placebo (Drug)
Placebo and Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Behavioral Measures
时间窗: Baseline, +15, +80, +240
Subjective effects, perceptual alterations, and cognitive effects will be assessed using visual analog scales, Positive and Negative Symptom Subscale (PANSS), Clinician Administered Dissociative States Scale (CADSS), Psychotomimetic States Inventory (PSI) and a neuro cognitive battery.
次要结局
未报告次要终点
研究者
Mohini Ranganathan
Principal Investigator
Yale University